|
Market Closed -
Nasdaq
16:00:00 2026-09-03 EDT
|
5-day change | 1st Jan Change | ||
| 1.780 USD | -3.78% |
|
-16.04% | -85.40% |
Company Valuation: Tenax Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 26.21 | 4.979 | 6.553 | 218.5 | 494.6 | 102 | - | - |
| Change | - | -81.01% | 31.6% | 3,233.86% | 126.39% | -79.38% | - | - |
| Enterprise Value (EV) 1 | 26.21 | 4.979 | 6.553 | 218.5 | 494.6 | 16.76 | 91.76 | 102 |
| Change | - | -81.01% | 31.6% | 3,233.86% | 126.39% | -96.61% | 447.44% | 11.12% |
| P/E | -0.66x | -0.3x | -0.71x | -5.38x | -9.1x | -1.23x | -1.19x | -1.11x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0.1x | -0.6x | -0.15x | -0.36x | -0.15x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 8.5x |
| EV / Revenue | - | - | - | - | - | - | - | 8.5x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0.8x | -0.45x | -0.8x | -11.2x | -8.77x | -0.22x | -1.05x | -0.97x |
| EV / FCF | - | - | - | - | - | -0.34x | -1.06x | -0.79x |
| FCF Yield | - | - | - | - | - | -298% | -94.3% | -126% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2,528 | -600.8 | -31.04 | -1.15 | -1.34 | -1.452 | -1.5 | -1.608 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 12 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -32.73 | -11.05 | -8.234 | -19.49 | -56.38 | -75.97 | -87.2 | -104.9 |
| Net income 1 | -32.47 | -11.05 | -7.711 | -17.6 | -52.6 | -72.73 | -84.06 | -99.54 |
| Net Debt 1 | - | - | - | - | - | -85.2 | -10.2 | - |
| Reference price 2 | 1,664.000 | 178.238 | 21.968 | 6.190 | 12.190 | 1.780 | 1.780 | 1.780 |
| Nbr of stocks (in thousands) | 15.8 | 27.9 | 298 | 35,292 | 40,570 | 57,282 | - | - |
| Announcement Date | 3/29/22 | 3/31/23 | 3/28/24 | 3/25/25 | 3/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.27x | - | - | - | 106M | |
| 34.07x | 6.11x | 18.29x | 0.94% | 50.14B | |
| -21.38x | 253.2x | -23.09x | -.--% | 44.85B | |
| 33.98x | 3.29x | 14.19x | -.--% | 43.43B | |
| 47.39x | 5.49x | 30x | -.--% | 41.14B | |
| 28.29x | 8.56x | 21.63x | 0.41% | 32.92B | |
| 33.72x | 5.52x | 25.09x | -.--% | 16.55B | |
| 24.26x | 2.11x | 9.12x | 1.11% | 14.65B | |
| 78.05x | 4.1x | 15.91x | -.--% | 13.93B | |
| Average | 28.57x | 36.05x | 13.89x | 0.31% | 28.63B | |
| Weighted average by Cap. | 27.58x | 48.49x | 12.48x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TENX Stock
- Valuation Tenax Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
